Sriram Vaidyanathan, MBBS; Martyn Barnes, MBChB; Peter Williamson, MBChB; Pippa Hopkinson; Peter T. Donnan, MD; Brian Lipworth, MD
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M09-2840.
Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B. Combined Oral and Intranasal Corticosteroid Therapy for Nasal Polyps. Ann Intern Med. 2011;155:277-278. doi: 10.7326/0003-4819-155-4-201108160-00023
Download citation file:
Published: Ann Intern Med. 2011;155(4):277-278.
TO THE EDITOR:
We thank Drs. Mullol and Alobid (1) for bringing prominence to a much-ignored but debilitating illness and would like to discuss several points raised by their editorial. First, the editorial proposes that differences between groups in the primary outcomes of polyp size and olfaction do not endure at 28 weeks. Our interpretation of the data is that over the 28-week period, the significant overall differences were −1.1 units (95% CI, −1.5 to −0.6 unit; P < 0.001) for polyp score and 15.40 mm (CI, −25.85 to −4.95 mm; P = 0.004) for hyposmia score (Table 2 in the article) (2).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only